Background: This phase-II study was conducted to investigate the potential benefit from the addition of mitomycin to a conventional anthracycline-cisplatin-and 5-fluorouracil-based chemotherapy for recurrent and metastatic undifferentiated carcinoma of nasopharyngeal type (UCNT).
Introduction
Undifferentiated Carcinomas of Nasopharyngeal Type (UCNT) account for more than 90% of the nasopharyngeal malignancies and derive from an epidermoi'd lineage [1] . The carcinogenesis of UCNT is closely related to the Epstein-Barr virus, consumption of salted fish, and geographic and ethnic factors [2, 3] . UCNT is a fast-growing tumor characterized by frequent metastasis to lung, bone, and lymph nodes [4] . Several chemotherapy regimens [5, 6] have been investigated which yielded a high percentage of objective responses, with frequent complete responses of long duration.
Our three previous phase-II studies, performed in patients with localised and metastatic UCNT were based on drugs considered active in carcinomas of epidermoid origin such as cisplatin, 5-fluorouracil and anthracyclines [6] [7] [8] . Previous preclinical and clinical studies showed mitomycin to be an active drug in head and neck carcinomas [9] ; and that its combination with classical cisplatin-5-fluorouracil regimens render it possible to achieve 77% of objective responses, with 27% of complete responses in locally advanced UCNT [10] especially under the hypoxic conditions which are believed to exist in bulky tumors. Therefore, we decided to investigate the effects of the addition of mitomycin to the standard protocol in our institution (FEP: Combining 5-fluorouracil, epirubicin, and cisplatin) in patients with locally advanced or recurrent metastatic UCNT [11] .
Patients and methods

Inclusion criteria
Consecutive eligible patients with advanced histologically-documented UCNT (type II-III of the nasopharyngeal WHO classification) [1] with locally recurrent or metastatic disease were included in this study. All patients underwent a pre-therapy work-up including clinical history, physical examination, computed tomography (CT-scan), chest X-ray, abdominal ultrasound, bone scan, bone marrow biopsy, complete blood count, routine chemistries to check liver and renal functions, and Epstein-Barr virus (EBV) serology (IgG VCA, IgG EA, IgA VCA, IgA EA). Adequate renal (creatinine < 120 nmol/1), hematological (absolute neutrophil count > 2 x 1O 9 /I and platelets > 100 x 10 9 /l) and liver functions (ALT, AST ^ 2.5 N) were required for entry into the study and before each new treatment cycle. Additional abdominal and chest CT scans were performed to document baseline disease, to measure, and/or evaluate metastatic lesions detected by chest X-ray and abdominal ultrasound.
Treatment
Chemotherapy consisted of 800 mg/m 2 /day continuous infusion 5-fluorouracil from day 1 to day 4, in combination with 70 mg/m 2 epirubicin, 10 mg/m 2 mitomycin, and 100 mg/m 2 cisplatin on day 1, repeated every four weeks. A total of six cycles were planned Mitomycin was delivered only in cycles 1, 3 and 5.
Standard saline hyper-hydration (NaCl 0 9% six liters/24 hours) with mannitol-induced diuresis and a standard prophylactic antiemetic regimen with high-dose metoclopramide was given 30 minutes before the cisplatin administration.
Radiotherapy was planned in order to consolidate complete and/or partial responses obtained with chemotherapy on the primary cervical tumor, lymph nodes, and on bone metastases.
Evaluation of response and toxicity
Toxicity was evaluated after each cycle by clinical and biological examinations (complete blood count, routine chemistries), and electrocardiogram according to WHO criteria. A complete blood count was also performed once or twice between cycles. Response was evaluated according to the WHO criteria every 2-3 cycles of chemotherapy and at the end of chemotherapy before radiotherapy.
Complete response (CR) was defined as the disappearance of clinical and radiological tumor evidence. Partial response (PR) was defined as a greater than 50% reduction in the product of the two greatest perpendicular diameters of each measurable disease site. Stable disease (SD) was defined as tumor reduction of less than 50% or less than 25% progression. Disease progression (PD) was defined as a tumor volume increase of more than 25%. Treatment was discontinued immediately upon evidence of tumor progression or after four cycles for patients with SD.
Survival was calculated from the initiation of chemotherapy to the date of last follow-up or death. Time to progression was defined as the time between initiation of chemotherapy and progression, documented clinically and/or radiologically. Survival and time to progression were calculated by the Kaplan-Meier method [12] .
Results
Patient characteristics
Between July 1989 and December 1991, 44 consecutive patients were entered in this study. Thirty-four patients were treated at the 'Unite La Grange' of the Gustave Table 1 . Eleven patients (25%) had only loco-regional recurrences, 21 patients (47%) had only metastatic disease, and 12 (28%) had both loco-regional recurrences and distant metastasis.
Forty patients have been pre-treated with either BEC (bleomycin, epirubicin, cisplatin) neoadjuvant chemo- (50) 23 (52) Abbreviations: CR -complete response; PR -partial response; SD -stable disease; PD -progressive disease; OR -overall response.
therapy followed by locoregional radiotherapy (17 cases) or with locoregional radiotherapy alone (23 cases). The progression-free interval after primary chemotherapy varies from 12 to 45 months (median 18 months) and all of these patients were considered chemosensitive. Four patients with metastatic disease had not been previously treated. Compliance with treatment is summarized in Table 2 . Follow-up data were collected until December 1997. A total number of 218 chemotherapy cycles were given, with mitomycin administred in 103 (47%) of them. A median of five cycles were administered to each patient (range 3-8).
Toxicities
Chemotherapy-induced toxicities are summarized in Table 2 . Forty-four patients and 212 of 218 cycles were evaluable for toxicity.
Hematologic toxicity. Grade 3-4 neutropenia was observed in 39 of 44 patients (89%) and 122 of 212 cycles (57.5%), including 83 of 122 cycles (68%) with mitomycin. The median duration of neutropenia was 6.5 days (range 4-14 days). Febrile neutropenia was observed in 16 patients (36%) and in 24 of 212 cycles (11%). Grade 3-4 thrombocytopenia with no symptomatic bleeding or purpura was observed in 45 cycles (21%) and in 27 patients (61%), including 27 of 45 cycles (60%) with mitomycin. Grade 3 anemia was noted in 23 cycles (11%) and in 18 patients (40%). Anemia was related to treatment with mitomycin in 18 of 23 cycles (78%) and was simultaneous with grade 3-4 thrombocytopenia in 12 of 18 cycles. A 25% dose reduction due to hematologic toxicity was applied in 41 of 218 cycles (19%).
Non-hematologic toxicity. Severe grade 3-4 mucositis was observed in 25 cycles (11%) and 14 patients (32%). Mucositis occurred in 13 of 14 patients (93%) who had previously received radiation therapy in the head and neck areas. Grade 3 alopecia was frequently observed: 38 patients (86%). Other toxicities were infrequently observed, such as 5-fluorouracil-related transient cardiopathy in one patient, and a significant clinical cisplatinrelated oto-toxicity in three patients. Neither cutaneous toxicity (hand-foot syndrome) nor severe cisplatininduced neurotoxicity were reported.
There were four deaths among the patients treated in this study (9%). Three of them were related to febrile neutropenia (staphylococcus aureus septicemia in one patient; germs were not isolated in the other two patients). One 42-year-old patient died of cardiac failure probably related to the anthracycline-chemotherapy, having received a total epirubicin dose of 560 mg/m 2 .
Responses
All of the patients received three or more cycles of chemotherapy and were fully evaluable for response. Twenty-three patients (52%, 95% CI: 37%-68%) achieved objective responses including six CRs and 17 PRs. Objective responses were seen in all metastatic sites (liver, bone, extra-regional lymph-nodes) except for the lung metastasis. Fifteen instances of stable disease, two of them prolonged (8+ and 11 + months), were observed (Table 3) .
After chemotherapy, additional radiotherapy was given to 13 patients. Eight patients (two CR, five PR, and one SD) were irradiated on nasopharyngeal areas and cervical lymph node recurrences (65 Gy/33 fractions/seven weeks). One patient who was in CR after chemotherapy, with lymph node recurrence, was irradiated in the mediastinum (40 Gy/20 fractions/4 weeks).
Radiotherapy to bone metastasis sites (30 Gy/10 fractions/2 weeks) was delivered to five patients, (associated with the head and neck area irradiation in one case), whose response to chemotherapy was one PR and four SD. 
Survival
After a median follow-up of 87 months (71-100), with none of the patients lost to follow-up, the median duration of complete and partial response was 80 months and 10 months (2.5-50), respectively. The median duration of survival and the median time to progression were, respectively, 14 and nine months ( Figure 1) .
As of December 1997, five patients are alive in continuous complete remission at 75 to 90 months after treatment initiation.
Discussion
Metastatic UCNT could be taken as an example of a chemo-curable disease. Several studies have reported a small but consistent proportion of long-term diseasefree survivors among patients with metastatic UCNT, treated with cisplatin and/or anthracycline-based combination chemotherapy [15, 16] . Although there are no randomized trials testing the relative superiority of cisplatin-based chemotherapy, response rates have been consistently better with cisplatin-containing regimens [13] . Moreover, in the neoadjuvant setting, complete responses with cisplatin-5-fluorouracil or cisplatin-anthracycline combinations are three to four times higher in patients with UCNT than in patients with well-differentiated squamous cell carcinoma of the head and neck (HNSCC) [14] .
From 1986 to 1996, we conducted many phase II studies in patients with recurrent, metastatic, and locally advanced UCNT, testing several regimens sequentially designed to include different drugs with defined activity in carcinomas of epidermoid origin: 5-fluorouracil (F), bleomycin (B), epirubicin (E), and cisplatin (C) [6-8, 11, 17, 18] . The overall response rate achieved with these chemotherapy programs ranges between 45% and 75% (BFC regimen: 75%, BEC: 45%, FBEC: 69%) over a total of 147 treated patients with recurrent/metastatic UCNT. The time to progression in these studies ranges from 4 to 11 months.
Similar results have been reported by other groups. Recently, Siu et al. [19] of the Princess Margaret Hospital treated 61 patients with recurrent and/or metastatic UCNT with a five-drug combination, including cyclophosphamide, doxorubicin, cisplatin, methotrexate and bleomycin. The authors reported an objective response rate of 69% (11% CRs) with a median time to progression of seven months. The toxicity of this regimen was severe, with seven treatment-related deaths (10%). Chi et al. [20] reported their experience with a combination including cisplatin, 5-fluorouracil and folinic acid (PFL) in 22 patients. Objective responses were observed in 68% of patients, including 23% of CRs. The median survival ranged between 14 and 16 months. This regimen was well tolerated, and the median duration of response was five months.
Similarly, in the present study we observed a high number of objective responses (58%), including complete responses in 13% of patients. Responses were seen in several metastatic sites including bone and extraregional lymph nodes, and most importantly were also observed in patients with liver metastasis. The addition of radiotherapy to chemotherapy was effective in preventing loco-regional recurrence in patients achieving complete remission after chemotherapy. However, In terms of toxicity, the present study shows that the FMEP protocol seems to be less well tolerated than our previous cisplatin-based regimens. In the current study, severe febrile neutropenia was observed in 36% of patients, and severe thrombocytopenia in 61%; moreover, the incidence of toxic deaths (9%) appears to be higher than that observed (4% to 7%) in our previous studies [7, 8, 11, 21] .
In conclusion, the FMEP protocol has a good antitumor activity in patients with recurrent or metastatic disease but the addition of mitomycin to the 5-FUepirubicin-cisplatin combination did not increase the response rate in recurrent/metastatic disease. Moreover, the FMEP regimem is associated with excessive toxicity that makes it unsuitable for inclusion in first-line chemotherapy for patients with UCNT. Therefore, on the basis of our experience, the FEC regimen remains the gold standard chemotherapy in the first-line treatment of patients with advanced UCNT in our institutions, in both recurrent and metastatic settings.
At present, about 10% of patients with recurrent/ metastatic UCNT treated with cisplatinum-based regimens can have a long-term disease-free period [21, 22] . Moreover, long-term remissions are achieved in patients with loco-regional relapses, especially when anthracycline-cisplatin-based chemotherapy is followed by reirradiation to the site of relapse [23] .
Future strategies should aim to increase the diseasefree and overall survivals in patients with UCNT. It would be interesting to investigate whether the addition of new drugs such as taxanes or topoisomerase inhibitors can increase the response rate and the curability of patients with UCNT. Phase-II trials have already been initiated with paclitaxel in monotherapy and in combi-nation and have been associated with interesting results in preliminary reports [24, 25] .
